Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Praxis Precision Medicines to Participate in Goldmans Sachs 47th Annual Global Healthcare Conference

globenewswire.com
PRAX Praxis Precision Medicines announced participation in the Goldman Sachs Global Healthcare Conference. The article provides a corporate overview and details about the company's focus on CNS disorders and its development platforms.

Praxis Precision Medicines to Participate in Goldmans Sachs 47th Annual Global Healthcare Conference BOSTON, June 04, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced it will be presenting a corporate overview at the Goldman Sachs 47 th Annual Global Healthcare Conference 2026 taking place in Miami, FL at the Loews Miami Beach Hotel on Monday, June 8, 2026 at 8:00am ET.

A live webcast of the event will be available through this link. A replay of the event will also be available on Praxis’ “ Events and Presentations” website after each event for approximately 180 days.

About Praxis

Praxis Precision Medicines is a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four late-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook , LinkedIn and X/Twitter.